Zydus Lifesciences Ltd

📈 Zydus Lifesciences: 17% Revenue Growth, 31.2% EBITDA Margin, US Launch, & Rs. 1,100 Cr Buyback

- Consolidated revenues: Rs. 271.5B (17% growth prev yr)

- EBITDA margin: 31.2%

- US launch for saroglitazar planned Q4 FY2027

- Saroglitazar: nearly 4 million patients in 2025, cumulative almost 17 million

- Tishtha biosimilar: over 25,000 patients in 7 months, around 70% more accessible

- Share buyback up to Rs. 1,100 crore at Rs. 1,260/share

- Dividend declared Re. 1/- (100%) for FY 2025-26

- R&D investment approximately 8% of revenues

- Renewable energy 42% of energy mix; GHG intensity down 19% in 2 years

- Global workforce ~30,000, >1,500 R&D scientists